课题基金 / 基金详情

HTS Cell Based EFC Assays for GPCR Drug Discovery(RMI)

HTS Cell Based EFC Assays for GPCR Drug Discovery(RMI)
基于 HTS 细胞的 EFC 检测用于 GPCR 药物发现 (RMI)
批准号:
7018985
负责人:
PYARE L KHANNA
金额:
$14.43万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-30 至 2006-08-31

项目摘要

项目成果

PYARE L KHANNA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):GPCRs调节体内神经递质和激素的许多细胞活动,以及制药行业销售的近一半药物的治疗效果,一直是药物发现的重要分子靶点。对人类基因组的测序发现了多达800个gpr基因,其中大多数是配体未知的孤儿。这些孤立的GPCR代表了发现新疗法的大量独特的分子靶点。利用激动剂与GPCRs结合导致B-arrestin从胞浆移位到GPCRs的基本发现,我们建议开发一种新的药物高温合成方法来对抗孤儿GPCRs。B-arrestin的转运通常是用共聚焦显微镜来测量的,这是一种低通量、昂贵且不易受HTS影响的方法。我们建议使用我们的酶片段互补(EFC)技术来开发一种简单的B-arrestin转运试验,该方法很容易适应HTS,可以检测蛋白质在细胞内的易位。该检测是基于一种极其敏感的B-半乳糖苷酶(B-GAL)互补技术,该技术利用了两个基因工程的大肠杆菌B-半乳糖苷酶片段。较大的片段酶受体(EA)在氨基末端附近有缺失,而较小的片段ProLabel含有EA缺失的氨基末端序列。单独一家,艺电是不活跃的。然而,在体外,它可以自发地与Pro-Label重新结合,形成一种活性酶,催化形成可以用光度法检测的发光产物。这笔赠款的目标将是使用我们的EFC技术来测量B-arrestin易位,以响应GPCR的激活,作为孤儿GPCRs和一般GPCRs的高度敏感的药物发现试验。这项技术还可以用来识别GPCRs的变构调节剂,这是一类新型的药物,可以改变GPCRs的敏感性和激活程度,而不直接与配体结合域相互作用。已知的变构调节剂是离子和G蛋白,它们影响GPCRs与激动剂和药物(如MPEP)的亲和力,这些药物通过一些代谢性受体拮抗传递,而不影响激动剂的结合。变构调节剂可以有新的治疗用途,因为它们主要作用于受体被刺激时,从而缓和受体的递质和激动剂激活。在这笔赠款中,我们将测试所开发的GPCREFC分析是否可以作为一种灵敏的分析来鉴定GPCR变构调节剂,以提供一种全新的GPCR药物发现途径。
英文摘要
DESCRIPTION (provided by applicant): GPCRs mediate many of the cellular actions of neurotransmitters and hormones in the body as well as the therapeutic effects of almost half of the drugs sold by the pharmaceutical industry and have been important molecular targets for drug discovery. The sequencing of the Human Genome has revealed as many as 800 GPCR genes, most of which are orphans with not known ligands. These orphan GPCRs represent a large pool of unique molecular targets for the discovery of new therapeutics. We propose to develop a novel approach for HTS of drugs against orphan GPCRs employing the basic finding that agonist binding to GPCRs causes the translocation of B-arrestin from the cytosol to the GPCR. B arrestin trafficking is usually measured by confocal microscopy which is low throughput, expensive and not easily amenable for HTS. We propose to develop a simple B-arrestin trafficking assay that is easily amenable for HTS using our enzyme fragment complementation (EFC) technology that can detect the intracellular translocation of proteins. The assay is based on an extremely sensitive B galactosidase (B-gal) complementation technology that utilizes 2 genetically engineered fragments of E. coli B-gal. The larger fragment, Enzyme Acceptor (EA), contains a deletion near the amino terminus, while the smaller fragment, ProLabel, contains the amino-terminal sequence missing from EA. Alone, EA is inactive. However, in vitro it can spontaneously recombine with Pro-label to form an active enzyme that catalyzes the formation of a luminescent product that can be detected photometrically. The objective of this grant will be to use our EFC technology to measure B-arrestin translocation in response to GPCR activation as a highly sensitive drug discovery assay for orphan GPCRs and GPCRs in general. This technology could also be used to identify allosteric modulators of GPCRs which are a novel class of drugs that modify sensitivity and extent of GPCR activation without directly interacting with the ligand binding domains. Known allosteric modulators are ions and G proteins, which affect the affinity of GPCRs for agonists and drugs such as MPEP that antagonize transmission via some metabotrophic receptors without affecting agonist binding. Allosteric modulators can have novel therapeutic uses since they primarily act when the receptor is stimulated, thereby tempering transmitter and agonist activation of the receptor. In this grant, we will test whether the GPCR EFC assay developed can be employed as a sensitive assay to identify GPCR allosteric modulators to provide a totally novel avenue of GPCR drug discovery.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HTS Technology for Discovery of Drugs Targeting GPCR Oligomers
  • 批准号:
    7169394
  • 项目类别:
  • 资助金额:
    $15.63万
  • 财政年份:
    2006
  • 负责人:
    PYARE L KHANNA
  • 依托单位:
Novel Drug Screening Assays for Orphan GPCRs
  • 批准号:
    7162821
  • 项目类别:
  • 资助金额:
    $15.12万
  • 财政年份:
    2006
  • 负责人:
    PYARE L KHANNA
  • 依托单位:
EFC Assay to Measure Growth Factor Receptors
  • 批准号:
    6831849
  • 项目类别:
  • 资助金额:
    $13.14万
  • 财政年份:
    2004
  • 负责人:
    PYARE L KHANNA
  • 依托单位:
Cell Based EFC Assay for Protease Drug Discovery
  • 批准号:
    6688470
  • 项目类别:
  • 资助金额:
    $12.2万
  • 财政年份:
    2003
  • 负责人:
    PYARE L KHANNA
  • 依托单位:
国内基金
海外基金
AT1R-G蛋白/β-arrestins通路偏好性激活在急性肾损伤中的作用及其机制
  • 批准号:
    82104272
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    贾英丽
  • 依托单位:
催产素受体Gαq与β-arrestins偏爱型信号通路在产后抑郁症中的作用
  • 批准号:
    82104148
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    朱佳蕾
  • 依托单位:
β-arrestins在DC细胞迁移及自身免疫疾病中的作用及机制研究
  • 批准号:
    31871404
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2018
  • 负责人:
    杜昌升
  • 依托单位:
β-arrestins调节小胶质细胞M1/M2表型转化及其在阿尔兹海默病进程中的作用
  • 批准号:
    81703488
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.1万元
  • 批准年份:
    2017
  • 负责人:
    方吟荃
  • 依托单位: